A plaintiff, Judy W., has filed a products liability lawsuit against the manufacturers of Taxotere, Sanofi S.A. and Aventis Pharma S.A., alleging permanent hair loss due to taking Taxotere for chemotherapy treatment.

According to the permanent hair loss after Taxotere lawsuit, Judy is a resident of the state of Louisiana. She alleges that she began taking the medication in March 2007 through May 2007.

Judy, in the permanent hair loss after Taxotere lawsuit, is alleging the following counts: 1) Strict Products Liability- Failure to Warn; 2) Strict Products Liability for Misrepresentation; 3) Negligence; 4) Negligent Misrepresentation; 5) Fraudulent Misrepresentation; 6) Fraudulent Concealment; 7) Fraud and Deceit; and 8) Breach of Express Warranty.

Judy’s claim is filed as part of a large multidistrict litigation, or MDL, centered on allegations that the use of Taxotere as a chemotherapy drug causes permanent hair loss after Taxotere use, which is also known as alopecia.

Permanent Hair Loss After Taxotere Facts

Women like Judy are filing permanent hair loss after Taxotere lawsuits alleging that the drug, used as treatment for chemotherapy causes them to suffer from permanent alopecia, or hair loss, and allege that they were never warned about these adverse side effects and complications before the drug’s use.

The difference with Taxotere is that women who undergo chemotherapy treatment with other drugs are aware and expect that they might suffer from hair loss. However, the expectation is that their hair will eventually grow back and that this hair loss is only temporary. Their hair should be able to grow back once chemotherapy treatment is done.

In the permanent hair loss after Taxotere lawsuits, women allege that they were never warned that permanent alopecia may result.

The permanent hair loss after Taxotere lawsuit further alleges and maintains that Sanofi had warned of potential adverse side effects and complications in Europe and Canada, but never alerted the U.S.  patients of such warnings. Taxotere has been selling in the U.S. since 2004.

The permanent hair loss after Taxotere lawsuit claims that Sanofi knew or should have known of the alopecia side effects but failed to give out proper warnings of such risks, they failed to sufficiently test Taxotere for these risks, there was negligence in the manufacturing, designing, and representation/marketing of Taxotere and they sold a hazardous, defective, and unsafe medication.

Additionally, the lawsuit rests the obligation and responsibility for producing and selling a product that is not unsafe and dangerous for patient use on the shoulders of the manufacturers and blames them for allowing patients and victims of this medication to suffer from permanent hair loss due to these alleged omissions and acts.

By filing a permanent hair loss after Taxotere lawsuit, a person may recover substantial gains from their Taxotere-related losses.

The Taxotere Breast Cancer Treatment Lawsuit is Case No. 2:17-cv-10791-KDE-MBN, in the U.S. District Court for the Eastern District of Louisiana. The Taxotere Lawsuit MDL is In re: Taxotere (Docetaxel) Products Liability Litigation, MDL No 2740, in the U.S. District Court for the Eastern District of Louisiana.